Objective  To investigate the mechanism of Yangxin Xiaobi decoction in the treatment of stable angina pectoris by network pharmacology.

Methods  The main active components and its predicted targets of Yangxin Xiaobi decoction were screened in Traditional Chinese Medicine Systems Pharmacology (TCMSP). The related therapeutic targets of stable angina pectoris were obtained from DrugBank and Therapeutic Target Database (TTD). Subsequently, protein-protein interaction network were constructed by STRING database, and the network diagrams of active ingredient-therapeutic targets of stable angina pectoris target were drawn using Cytoscape software.

Results  A total of 126 targets of Yangxin Xiaobi decoction in the treatment of stable angina pectoris were screened, and 2 305 interactions were obtained. According to their degree values, quercetin, kaempferol, luteolin, β-sitosterol and tanshinone IIA were the top 5 compounds in the network. The results of GO and KEGG analysis showed that Yangxin Xiaobi decoction might exert beneficial effects on stable angina pectoris by affecting the biological processes including movement of cell components, lipid localization, oxidative stress, DNA transcription, coagulation process, adenosine triphosphate metabolism, anti-regulation of immunity and inflammation, calcium ion transport, etc. Furthermore, the hypoxia inducible factor-1, Toll-like receptors, C-type lectin receptors, fluid shear and atherosclerosis, T helper cell 17/interleukin-17, T cell receptors, tumor necrosis factor, relaxin, advanced glycation end products and the signaling pathways of its receptor may get involved in the process.

Conclusion  The material basis and mechanism of Yangxin Xiaobi decoction in treating stable angina pectoris may be related to the the above-mentioned chemical components and related-biological processes and signaling pathways.

1.胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220. [Hu SS, Gao RL, Liu LS, et al. Summary of the 2018 report on cardiovascular diseases in China[J]. Chinese Circulation Journal, 2019, 34(3): 209-220.] DOI: 10.3969/j.issn.1000-3614.2019.03.001.

2.Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association[J]. Circulation, 2020, 141(9): e139-e596. DOI: 10.1161/CIR.0000000000000757.

3.Shao C, Wang J, Tian J, et al. Coronary artery disease: from mechanism to clinical practice[J]. Adv Exp Med Biol, 2020, 1177: 1-36. DOI: 10.1007/978-981-15-2517-9_1.

4.李慧敏, 熊兴江, 赵晖, 等. 近3年中医药治疗稳定型心绞痛随机对照试验结局指标的现状分析[J]. 北京中医药大学学报, 2020, 43(7): 606-616. [Li HM, Xiong  XJ, Zhao H, et al. Analysis of outcomes used in RCTs of traditional Chinese medicine on stable angina pectoris in the past 3 years[J]. Journal of Beijing University of Traditional Chinese Medicine, 2020, 43(7): 606-616.] DOI: 10.3969/j.issn.1006-2157.2020.07.013.

5.姜永英, 文随生, 苏仁强, 等. 养心消痹汤结合内关穴位埋线对稳定型心绞痛患者血清白介素-6水平的影响[J]. 湖北中医杂志, 2014, 36(11): 8-9. [Jiang YY, Wen SS, Su RQ, et al. Effect of Yangxinxiaobi decoction combined with Neiguan acupoint catgut embedding therapy on serum IL-6 level in patients with stable angina pectoris[J]. Hubei Journal of TCM, 2014, 36(11): 8-9.] https://www.cnki.com.cn/Article/CJFDTOTAL-HBZZ201411001.htm.

6.苏仁强, 李伟华, 张森, 等. 养心消痹汤结合内关穴位埋线治疗稳定型心绞痛临床观察[J]. 湖北中医杂志, 2014, 36(5): 15-16. [Su RQ, Li WH, Zhang S, et al. Clinical obeservation of Yangxinxiaobi decoction combined with thread-embedding in Neiguan for stable angina[J]. Hubei Journal of TCM, 2014, 36(5): 15-16.] https://www.cnki.com.cn/Article/CJFDTOTAL-HBZZ201405010.htm.

7.涂慧, 陈林, 周代俊, 等. 基于指纹图谱和网络药理学对经典名方五味消毒饮质量标志物的预测分析[J]. 中国药师, 2024, 27(4): 557-569. [Tu H, Chen  L, Zhou  DJ, et al. Quality marker prediction analysis of Wuwei disinfection decoction based on fingerprint and network pharmacology[J]. China Pharmacist, 2024, 27(4): 557-569.] DOI: 10.12173/j.issn.1008-049X.202401123.

8.肖娟兰, 张东旭, 赵鹿, 等. 基于网络药理学和分子对接法探讨安神补心六味丸治疗冠心病的作用机制 [J]. 中国药师, 2021, 24(7): 240-252. [Xiao JL, Zhang  DX, Zhao L, et al. Mechanism of Anshen Buxin six pills in the treatment of coronary heart disease based on network pharmacology and molecular docking[J]. China Pharmacist, 2021, 24(7): 240-252.] DOI: 10.19962/j.cnki.issn1008-049X.2021.07.007.

9.Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks[J]. Bioinformatics, 2009, 25(8): 1091-1093. DOI: 10.1093/bioinformatics/btp101.

10.Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data[J]. Bioinformatics, 2013, 29(5): 661-663. DOI: 10.1093/bioinformatics/btt019.

11.Chekalina N, Burmak Y, Petrov Y, et al. Quercetin reduces the transcriptional activity of NF-κB in stable coronary artery disease[J]. Indian Heart J, 2018, 70(5): 593-597. DOI: 10.1016/j.ihj.2018.04.006.

12.Dabeek WM, Marra MV. Dietary quercetin and kaempferol: bioavailability and potential cardiovascular-related bioactivity in humans[J]. Nutrients, 2019, 11(10): 2288. DOI: 10.3390/nu11102288.

13.Li L, Luo W, Qian Y, et al. Luteolin protects against diabetic cardiomyopathy by inhibiting NF-kappaB-mediated inflammation and activating the Nrf2-mediated antioxidant responses[J]. Phytomedicine, 2019, 59: 152774. DOI: 10.1016/j.phymed.2018.11.034.

14.Zhang GX, Zhang YY, Zhang XX, et al. Different network pharmacology mechanisms of Danshen-based Fangjis in the treatment of stable angina[J]. Acta Pharmacol Sin, 2018, 39(6): 952-960. DOI: 10.1038/aps.2017.191.

15.Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need[J]. Heart, 2018, 104(4): 284-292. DOI: 10.1136/heartjnl-2017-311446.

16.Zhang Y, Yang X, Bian F, et al. TNF-alpha promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-kappaB and PPAR-gamma[J]. J Mol Cell Cardiol, 2014, 72: 85-94. DOI: 10.1016/j.yjmcc.2014.02.012.

17.Xing SS, Yang XY, Zheng T, et al. Salidroside improves endothelial function and alleviates atherosclerosis by activating a mitochondria-related AMPK/PI3K/Akt/eNOS pathway[J]. Vascul Pharmacol, 2015, 72: 141-152. DOI: 10.1016/j.vph.2015.07.004.

18.李汉源, 张森, 苏仁强, 等. 养心消痹汤结合内关穴位埋线对稳定型心绞痛患者血脂的影响[J]. 湖北中医杂志, 2014, 36(12): 8-9. [Li HY, Zhang S, Su RQ, et al. Effect of Yangxinxiaobi decoction combined with Neiguan acupoint catgut embedding therapy on blood lipids in patients with stable angina pectoris[J]. Hubei Journal of TCM, 2014, 36(12): 8-9.] https://www.cnki.com.cn/Article/CJFDTOTAL-HBZZ201412004.htm.

19.苏仁强, 李伟华, 张森, 等. 养心消痹汤结合内关穴埋线对稳定型心绞痛患者血清超氧化物歧化酶和丙二醛水平的影响[J]. 湖北中医杂志, 2014, 36(8): 3-5. [Su RQ, Li WH, Zhang S, et al. Effect of Yangxinxiaobi decoction combined with Neiguan acupoint catgut embedding on serum SOD and MDA levels in patients with stable angina pectoris[J]. Hubei Journal of TCM, 2014, 36(8): 3-5.] DOI: 1000-0704( 2014) 08-0003-03.